Merck KGaA to Divest CDMO Business to Lonza
Merck KGaA agreed to sell its CDMO business to Lonza for a mid-triple-digit million-euro amount. The deal, expected to close in mid-2027, includes five US sites and 1,100 employees. Merck aims to focus on innovation-driven businesses, while Lonza expands its US CDMO network.
How this was made
The 30-second read
Why it matters
The transaction transfers five US manufacturing sites and about 1,100 employees, including ADC, viral vector, and LNP capabilities, with Lonza expanding its US network and Merck retaining contract testing services.
Market read
A portfolio-focused divestiture plus CDMO consolidation deal that can affect advanced modality manufacturing capacity and customer sourcing over the 2027 closing timeline.
What to watch
Regulatory approval timing and integration of Merck’s ADC payload-linker, viral vector, and LNP capabilities into Lonza’s operating model could drive outcomes more than the headline portfolio focus.
Background
Merck KGaA is selling its CDMO business to Lonza, positioning Life Science around innovation-driven activities while keeping downstream consumables, technologies, and services.
Market effects
Signals consolidation in CDMO capacity for ADCs, viral vectors, and LNPs, potentially reshaping customer sourcing and competitive positioning.
Expands Lonza’s US CDMO footprint from four to nine sites, increasing US manufacturing capacity for advanced modalities.
Rebalances global ADC and advanced drug delivery manufacturing networks between Merck and Lonza, with knock-on effects for biopharma supply chains.
Counterpoint
The deal’s financial impact may be limited until mid-2027 closing, so near-term trading could be more about execution risk than fundamentals.
Key entities
- companyMerck KGaA
Seller of its CDMO business, including ADC, viral vector, and LNP manufacturing sites in the US.
- companyLonza Group
Buyer expanding its US CDMO network to nine sites and integrating Merck’s advanced modality capabilities.
